

Drug List Per Act 165

RECOMMENDATIONS FOR CONSIDERATION
INCLUDES ALL DOSAGE FORMS ON THE LIST

Rank	Brand/ (Cost) Generic	Brand Name	Generic Name	Labeler	Therapeutic Class	1 Year Avg. WAC* % Change	5 Year Avg. WAC* % Change
1	Brand	ABILIFY	Aripiprazole	OTSUKA AMERICA	Quinolinone Derivatives		55.27%
2	Brand	CRESTOR	Rosuvastatin Calcium	ASTRAZENECA LP	HMG CoA Reductase Inhibitors	20.75%	75.98%
3	Generic	DOXYCYCLINE HYCLATE	Doxycycline Hyclate	MUTUAL PHARMACEUTICAL COMPANY	Tetracyclines		4787.61%
4	Brand	ENBREL	Etanercept	AMGEN/IMMUNEX	Soluble Tumor Necrosis Factor Receptor Agents	16.42%	92.73%
5	Brand	EPIPEN	Epinephrine	MYLAN SPECIALTY	Anaphylaxis Therapy Agents	32.02%	205.45%
6	Brand	HUMIRA	Adalimumab	ABBOTT LABORATORIES	Anti-TNF-alpha - Monoclonal Antibodies	27.95%	113.79%
7	Brand	LANTUS	Insulin Glargine	AVENTIS PHARMACEUTICALS	Human Insulin		89.83%
8	Brand	LATUDA	Lurasidone HCl	SUNOVION PHARMACEUTICALS, INC.	Antipsychotics - Misc.	19.80%	99.68%
9	Brand	LIDODERM	Lidocaine	ENDO PHARMACEUTICALS, INC.	Local Anesthetics - Topical	25.00%	67.40%
10	Generic	METFORMIN HCL ER	Metformin HCl	LUPIN PHARMACEUTICALS, INC.	Biguanides	200.00%	

* WAC - Wholesale Acquisition Cost across various strengths, representing different brands/generics and therapeutic classes
 1 Year Average increase > 15%
 5 Year Average increase > 50%